Amylyx Pharmaceuticals (AMLX) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 4, 2026, with voting available online, by phone, or by mail for shareholders of record as of April 10, 2026.

• Key proposals include electing two Class II directors, ratifying Deloitte as auditor for 2026, and a non-binding advisory vote on executive compensation.

• Proxy materials and the 2025 Annual Report are available online, with options for shareholders to request paper copies.

Voting matters and shareholder proposals

• Shareholders will vote on electing two Class II directors for terms ending in 2029, ratifying Deloitte as auditor, and approving executive compensation on an advisory basis.

• Shareholder proposals for the 2027 meeting must be submitted by December 24, 2026, for proxy inclusion, or between February 4 and March 6, 2027, for other business.

• Shareholders may recommend director candidates and submit proposals following specific advance notice procedures.

Board of directors and corporate governance

• The board consists of seven members divided into three classes with staggered terms; five are independent under Nasdaq and SEC rules.

• Committees include audit, compensation, nominating and corporate governance, and science and technology, each with defined charters and responsibilities.

• The board emphasizes diversity, regular attendance, and prohibits hedging and pledging of company stock by insiders.

• Board leadership is separated from executive management, with risk oversight conducted through board committees.